Ethyl biscoumacetate
Pharmaceutical drug
- B01AA08 (WHO)
- 3,3-(ethyl acetate-methylene)-bis(4-hydroxycoumarin)
- 548-00-5
N
- 11047
- DB08794
Y
- 10444159
Y
- 08KL644731
- D07131
Y
- ChEMBL2106261
N
- DTXSID3057771
![Edit this at Wikidata](http://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png)
InChI
- InChI=1S/C22H16O8/c1-2-28-20(25)15(16-18(23)11-7-3-5-9-13(11)29-21(16)26)17-19(24)12-8-4-6-10-14(12)30-22(17)27/h3-10,15,23-24H,2H2,1H3
Y
- Key:JCLHQFUTFHUXNN-UHFFFAOYSA-N
Y
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Ethyl biscoumacetate is a vitamin K antagonist.
References
- The Merck Index, 12th Edition. 3818
- v
- t
- e
Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)
Glycoprotein IIb/IIIa inhibitors |
|
---|---|
ADP receptor/P2Y12 inhibitors | |
Prostaglandin analogue (PGI2) | |
COX inhibitors | |
Thromboxane inhibitors | |
Phosphodiesterase inhibitors | |
Other |
Vitamin K antagonists (inhibit II, VII, IX, X) |
| ||||
---|---|---|---|---|---|
Factor Xa inhibitors (with some II inhibition) |
| ||||
Direct thrombin (IIa) inhibitors |
| ||||
Other |
fibrinolytics
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e